A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00105443 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

602

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo

Sponsor

Bayer